Scancell Holdings plc (SCLP) Ord GBP0.001
0.15p
(1.52%)
- Add to watchlist
- Create an alert
- This stock can be held in a
0.15p
(1.52%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
0.15p
(1.52%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Share news, reports & tips
-
Scancell reports strong results from Immunobody trial
7 November 2025 12:54
(Sharecast News) - Scancell Holdings reported strong phase two results for its Immunobody iSCIB1+ cancer immunotherapy on Friday, showing significant improvements in progression-free survival for patients...
-
Scancell narrows loss as it progresses immunotherapy pipeline
11 September 2025 14:30
(Sharecast News) - Scancell reported progress across its immunotherapy pipeline on Thursday, as it narrowed annual losses and prepared for late-stage development of its lead melanoma treatment.
-
Scancell starts dosing next cohort in melanoma treatment study
25 June 2025 12:56
(Sharecast News) - Scancell announced on Wednesday that it has started dosing patients in cohort four of its phase 2 'SCOPE' clinical trial, evaluating the intradermal administration and...
-
Scancell shares jump on new antibody agreement with major biotech firm
12 June 2024 07:53
(Sharecast News) - Scancell Holdings saw shares surge on Wednesday after the the AIM-listed oncology immunotherapies group announced an agreement with a "major international biotechnology company".
-
Scancell appoints healthcare finance veteran as new CFO
29 August 2023 14:27
(Sharecast News) - Immunotherapy developer Scancell announced the appointment of Sath Nirmalananthan as its new chief financial officer on Tuesday, effective immediately.
-
Scancell to present positive recent findings at oncology summit
2 June 2023 13:18
(Sharecast News) - Immunotherapy developer Scancell said on Friday that it is set to present an informative poster at the American Society of Clinical Oncology Meeting (ASCO) 2023 annual meeting in Chicago...
-
Scancell shares jump on positive cancer vaccine progress
21 February 2023 12:14
(Sharecast News) - Immunotherapy developer Scancell announced the completion of the monotherapy dose-finding arm of the phase 1 and 2 'ModiFY' clinical trial on Tuesday.
Company announcements Announcements
-
Research Update
7 November 2025 07:00
Scancell Holdings
-
Result of AGM
30 October 2025 15:30
Scancell Holdings
-
Notice of AGM
3 October 2025 07:00
Scancell Holdings
-
Director Dealing
16 September 2025 07:00
Scancell Holdings
-
Final Results
11 September 2025 07:00
Scancell Holdings
-
Notice of Results
4 September 2025 07:00
Scancell Holdings
-
Director Dealing
8 August 2025 12:31
Scancell Holdings
-
Director/PDMR Shareholding
4 August 2025 10:23
Scancell Holdings
-
Strong Phase 2 data on iSCIB1+ in Melanoma
22 July 2025 07:00
Scancell Holdings
-
Share Option Exercise
16 July 2025 07:00
Scancell Holdings
-
Scancell initiates new arm in SCOPE Phase 2 study
25 June 2025 07:00
Scancell Holdings
-
Director Dealing
21 May 2025 07:00
Scancell Holdings
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2025. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.